CRISPR-Cas Type I-F3 Transposon Systems for DNA Integration Patent Application
Summary
USPTO published patent application US20260110001A1 disclosing recombinant Type I-F3 transposon-associated CRISPR-Cas systems and methods for DNA integration. The application, filed June 7, 2023 by inventors Rodolphe Barrangou and Avery Roberts under application number 18872321, covers CRISPR-Cas nucleic acid constructs combined with Tn7-like transposon systems. This publication makes the invention publicly available for examination and potential licensing or competing development.
“This invention relates to recombinant nucleic acid constructs encoding Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and transposon 7-like (Tn7-like) transposon systems for DNA integration, as well as methods of using the same.”
About this source
GovPing monitors USPTO Patent Applications - Biotech (C12N) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 199 changes logged to date.
What changed
USPTO published patent application US20260110001A1 for recombinant Type I-F3 transposon-associated CRISPR-Cas systems and transposon 7-like transposon systems for DNA integration. The application was filed June 7, 2023 by Rodolphe Barrangou and Avery Roberts. The invention covers recombinant nucleic acid constructs encoding these systems and methods of using them for DNA integration.
Affected parties including biotechnology and pharmaceutical companies should review this publication for freedom-to-operate analysis, patent landscape assessment, and potential licensing opportunities. Competitors developing similar CRISPR-Cas or transposon-based DNA integration technologies may need to evaluate potential infringement exposure once the application proceeds to grant.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
RECOMBINANT TYPE I-F3 TRANSPOSON-ASSOCIATED CRISPR-CAS SYSTEMS AND METHODS OF USE
Application US20260110001A1 Kind: A1 Apr 23, 2026
Inventors
Rodolphe BARRANGOU, Avery ROBERTS
Abstract
This invention relates to recombinant nucleic acid constructs encoding Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)-Cas systems and transposon 7-like (Tn7-like) transposon systems for DNA integration, as well as methods of using the same.
CPC Classifications
C12N 15/902 C12N 9/224 C12N 15/11 C12N 15/74 C12N 2310/20
Filing Date
2023-06-07
Application No.
18872321
Named provisions
Related changes
Get daily alerts for USPTO Patent Applications - Biotech (C12N)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Biotech (C12N) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.